INMB Q4 2023 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28,000-71.1% YoY

Gross Profit

$28,000100.0% margin

Operating Income

-$8M-29925.0% margin

Net Income

-$8M-30028.6% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

-34.9%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$57M

Total Liabilities

$19M

Stockholders' Equity

$38M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28,000	$97,000	-71.1%
Gross Profit	$28,000	$97,000	-71.1%
Operating Income	-$8M	-$6M	-48.5%
Net Income	-$8M	-$6M	-44.1%